ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / QNTM
TXMD (34) AYTU (27) COCP (36) AKTX (37) ⌘ Pro Terminal →

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) — RQD Stock Rating Cockpit

$2.38 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.36

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $20.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QNTM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.38 (-2.46% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, QNTM ranks #343 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QNTM compare to TXMD and AYTU in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QNTM?
▼

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.37 (-0.63%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.5% Base Target
$13 Bull$2 Base$2 Bear
📬 FREE QNTM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNTM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY QNTM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($564.3K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$2.89-15.9% Next Q
Q2 (-2Q)
51
Grade C-$2.43-4.5% Next Q
Q3 (-1Q)
49
Grade D$2.32+2.6% Next Q
Current
46
Grade D$2.38-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QNTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QNTM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.08) and Max Pain ($2.50) forces dealer call-delta covering toward $13.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QNTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QNTM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE3% OF RANGE
L: $2$2.38H: $12
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on QNTM

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (35)

12/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like QNTM
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNTM)

  • ✓Walkthrough of QNTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QNTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.23%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.44H $2.44L $2.38C $2.38VOL 76.9K
RES: $4.31SUP: $1.95SMA50: $3.08SMA200: $3.83
$11.42$8.89$6.36$3.83$1.31RES $4.31SUP $1.95$2.382026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNTM Butterfly Map → + Track QNTM →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QNTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QNTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNTM)

Health Care Rank #343 of 1016 ⚔️ TXMD vs QNTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNTM vs. TXMD, AYTU, COCP, AKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) ranks #343 by composite RQD confidence (46/100, grade D) and #831 by equity capitalization ($20.2M). Within this direct 5-issuer industry benchmark cohort, QNTM leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QNTM ACTIVE
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
D 46/100 — — — -2.46% $20.2M Benchmark Subject
TXMD
TherapeuticsMD Inc.
E 34/100 — — -12.9% -1.64% $20.8M /txmd-vs-qntm →
AYTU
Aytu BioPharma Inc.
E 27/100 — 69.0% -35.0% -2.52% $21.0M /aytu-vs-qntm →
COCP
Cocrystal Pharma Inc.
D- 36/100 — — -35.0% +1.53% $19.2M /cocp-vs-qntm →
AKTX
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% +3.00% $18.8M /aktx-vs-qntm →

2. QNTM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $20.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. QNTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.38 (-2.46% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, QNTM ranks #343 in composite RQD confidence.

How does QNTM compare to TXMD and AYTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QNTM?

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QNTM trading relative to its 50-day, 200-day, and 52-week technical levels?

QNTM last traded at $2.38 (-2.46% on volume of 76,851 shares), positioning the stock -22.73% below its 50-day simple moving average ($3.08) and -37.86% below its 200-day simple moving average ($3.83). Across its 52-week range of $2.07 to $12.42, QNTM sits at the 3.0% percentile with a 14-day RSI of 36.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.08 to $2.68).

QNTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell QNTM stock right now?

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is QNTM's 12-month price target and RQD AI Jury consensus?

QNTM's 12-month base price target is $2.25 (range $1.76 to $13.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: QNTM RQD Cockpit QNTM 12M Forecast QNTM Earnings & Move QNTM Dividends & DRIP QNTM Insiders & 13F QNTM Whale Options QNTM Profit Sankey QNTM News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

QNTM — Quantum Biopharma Ltd. Class B Subordinate Voting Shares: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:19:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

The RQD Score is 46 / D, labeled "Roarable Sell — Underperform / Distribution Warning," per the Roarable RQD rating. Across its five pillars:

  • Fundamental Cash Engine: 12 / 20. The pillar reports ROIC 0% and FCF yield 0%, per the Roarable RQD rating and market data. For a prospective investor, this means the source data shows no measurable return on invested capital or free-cash generation supporting the valuation.
  • Whale 13F Flow: 3 / 20. Scored on institutional accumulation and options positioning. This is the lowest pillar score, indicating weak institutional support in the source data.
  • Insider Conviction: 9 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow, per the Roarable RQD rating. The score signals limited insider-driven confidence signals in the data.
  • Macro Regime Fit: 9 / 20. Reflects Beta 1.0 and sector sensitivity, per the Roarable RQD rating. The stock's market sensitivity is neutral-to-market, offering no defensive or regime-specific tailwind in the data.
  • Forensic Balance Sheet: 13 / 20. Reports Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, per the Roarable RQD rating. This is the strongest pillar, though it remains a mid-range reading.

Taken together, the rating's tradeoff is that the balance sheet metrics are the most constructive element, while cash generation, institutional flow, and insider signals are weak. Valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data. The 52-week range of $2.07 - $12.46 against a current price of 2.44 (per market data) shows the stock trading near the low end of its recorded range.

Open Questions

  • What are the company's products, pipeline, and revenue sources, given that the source data contains no business description beyond sector and industry?
  • What are the reported revenue, operating income, net income, cash, and debt figures, since the financials section is empty?
  • Why do ROIC and FCF yield read 0%, and is the company currently generating any cash flow or earnings?
  • What institutional, insider, and Congressional trading activity exists, given that holders data is absent?
  • What catalysts or regulatory events are pending, since the news and catalysts section is empty?

QNTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QNTM Debate Forum (3) ↓
🔴 RISK WATCH Yahoo Finance • 25d ago
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QNTM Bull vs. Bear Conversation Board — What's Your Call at $2.38?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QNTM 🐻 50% BEARISH CONVICTION
1. Pick Your Side on QNTM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $2.64 (+8.2%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is QNTM (D • RQD 46/100) a Buy at $2.44?

Welcome to the QNTM (Quantum Biopharma Ltd. Class B Subordinate Voting Shares) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.95 (-20.1%)
Spot @ $2.44

Pump the brakes on QNTM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on QNTM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Quantum Biopharma Ltd. Class B Subordinate Voting Shares expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.88 (+18.0%)
Spot @ $2.44

QNTM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on QNTM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.44 (52-wk range $2.07 - $12.46), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%